Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The O-antigen of Shigella sonnei lipopolysaccharide is an immunodominant, high-molecular-weight polysaccharide that constitutes the distal, repeating glycan portion of the lipopolysaccharide (LPS) molecules on the outer membrane of Shigella sonnei. The O-antigen is highly species- and strain-specific, composed of unique repeating oligosaccharide units containing two rare sugars—2-acetamido-2-deoxy-L-altruronic acid (L-AltNAcA) and 2-acetamido-2-deoxy-L-fucose (FucNAc4N)—which are not found in other Shigella serogroups. This antigenic structure plays a central role in pathogenicity, immune recognition, and evasion, and is the molecular target for protective antibodies during infection and for vaccines. In S. sonnei, the O-antigen is encoded by genes on a virulence plasmid and is essential both for full virulence and for inducing a protective immune response. Conjugate vaccines and monoclonal antibodies targeting the O-antigen are under active development and have shown potential for disease prevention[1][2][3][4][5][6][7].
Induction of immune response: vaccine polysaccharide-protein conjugates (e.g., O-antigen conjugated to carrier proteins) elicit protective anti-O-antigen antibodies that mediate bacterial clearance[4][7]. Direct neutralization or bactericidal activity by monoclonal antibodies, leading to opsonization and complement-mediated killing[7].
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on O-antigen of Shigella sonnei lipopolysaccharide.